Mohammed A Alqahtani
Nova Southeastern University, USA
Title: Assessing the intention of healthcare providers to adopt biosimilars using the theory of planned behavior
Biography
Biography: Mohammed A Alqahtani
Abstract
It has been observed that spending on biological drugs has increased significantly in the United States (1). Around $2.0 billion was spent on biologic agents, nonfederal hospital costs and three of the top five most expensive drugs. Biological medications have also enhanced the quality of life and altered the progression of several life-threatening diseases or conditions (2). However, many reasons prevent the use of biological medicines, including the high manufacturing cost. Biological drugs are more expensive than conventional drugs (3); many patients cannot afford those (4). Recently, biosimilars have been offered as cost-effective and cost-saving alternatives (5). Nevertheless, studies have found that many healthcare providers have different perceptions that result in biosimilars not being used for their patients. Most physicians prefer originator products for biologic-naive patients and hesitate to switch from biologics to biosimilars.